GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Cyclically Adjusted PB Ratio

CytomX Therapeutics (STU:6C1) Cyclically Adjusted PB Ratio : 0.89 (As of Dec. 16, 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-12-16), CytomX Therapeutics's current share price is €1.01. CytomX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €1.14. CytomX Therapeutics's Cyclically Adjusted PB Ratio for today is 0.89.

The historical rank and industry rank for CytomX Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:6C1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.7   Med: 1.07   Max: 3.26
Current: 0.87

During the past years, CytomX Therapeutics's highest Cyclically Adjusted PB Ratio was 3.26. The lowest was 0.70. And the median was 1.07.

STU:6C1's Cyclically Adjusted PB Ratio is ranked better than
63% of 600 companies
in the Biotechnology industry
Industry Median: 1.545 vs STU:6C1: 0.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CytomX Therapeutics's adjusted book value per share data for the three months ended in Sep. 2024 was €-0.270. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.14 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CytomX Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CytomX Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Cyclically Adjusted PB Ratio Chart

CytomX Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.19

CytomX Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.19 1.61 0.93 0.92

Competitive Comparison of CytomX Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted PB Ratio falls into.



CytomX Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CytomX Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.01/1.14
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, CytomX Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.27/133.0289*133.0289
=-0.270

Current CPI (Sep. 2024) = 133.0289.

CytomX Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 -1.824 99.070 -2.449
201503 0.000 99.621 0.000
201506 1.623 100.684 2.144
201509 -2.705 100.392 -3.584
201512 3.212 99.792 4.282
201603 2.805 100.470 3.714
201606 2.489 101.688 3.256
201609 2.189 101.861 2.859
201612 2.039 101.863 2.663
201703 1.879 102.862 2.430
201706 1.262 103.349 1.624
201709 1.029 104.136 1.315
201712 1.535 104.011 1.963
201803 1.035 105.290 1.308
201806 0.903 106.317 1.130
201809 3.003 106.507 3.751
201812 2.552 105.998 3.203
201903 2.402 107.251 2.979
201906 1.978 108.070 2.435
201909 1.641 108.329 2.015
201912 1.011 108.420 1.240
202003 1.375 108.902 1.680
202006 1.131 108.767 1.383
202009 0.883 109.815 1.070
202012 -0.132 109.897 -0.160
202103 1.887 111.754 2.246
202106 1.668 114.631 1.936
202109 1.455 115.734 1.672
202112 -0.006 117.630 -0.007
202203 0.947 121.301 1.039
202206 0.701 125.017 0.746
202209 0.436 125.227 0.463
202212 -1.222 125.222 -1.298
202303 -1.220 127.348 -1.274
202306 -1.175 128.729 -1.214
202309 -0.718 129.860 -0.736
202312 -0.646 129.419 -0.664
202403 -0.428 131.776 -0.432
202406 -0.371 132.554 -0.372
202409 -0.270 133.029 -0.270

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytomX Therapeutics  (STU:6C1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CytomX Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytomX Therapeutics Business Description

Traded in Other Exchanges
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines